Compare 10X Genomics Inc (TXG) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs ProShares Ultra Gold ETF — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while ProShares Ultra Gold ETF trades at $45.31. The key difference: 10X Genomics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| TXG | UGL | |
|---|---|---|
Market Cap | $5.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $45.80 | $85.62 |
52-Week Low | $11.34 | $33.59 |
Enterprise Value | $5.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
UGL (ProShares Ultra Gold) trades at $43.39, down 0.41% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The ETF lacks fundamental financial ratios like P/E or P/B as it tracks gold futures. Recent news highlights gold's volatility amid Middle East tensions and interest rate uncertainty, with some analysts seeing a potential rebound from oversold conditions.
Outlook remains mixed: gold's safe-haven demand supports upside, but higher interest rates pose headwinds. Risks include Fed policy shifts and geopolitical developments. Institutional sentiment is cautious, with technicals favoring short-term bearishness despite some oversold signals suggesting potential stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
